Neurocrine (NBIX) Biosciences presented subgroup analyses and data from the KINECT-HD study showing the impact of Iingrezza – valbenazine – capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington’s disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores. A separate data analysis showed improvements in some aspects of emotional health with no worsening of psychiatric symptoms.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents data from Ingrezza studies on tardive dyskines patients
- Neurocrine presents data from long-term KINECT-4 study
- Neurocrine Biosciences’ $300M Share Buyback Plan: Potential Risks and Market Volatility Concerns
- Neurocrine Biosciences Reports Strong Q3 2024 Earnings
- Neurocrine reports Q3 non-GAAP EPS $1.81, consensus $1.50